These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20507361)

  • 21. Mechanisms of skin fibrosis in systemic sclerosis.
    Jinnin M
    J Dermatol; 2010 Jan; 37(1):11-25. PubMed ID: 20175837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic targets in systemic sclerosis.
    Denton CP
    Arthritis Res Ther; 2007; 9 Suppl 2(Suppl 2):S6. PubMed ID: 17767744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets.
    Gabrielli A; Svegliati S; Moroncini G; Luchetti M; Tonnini C; Avvedimento EV
    Autoimmun Rev; 2007 Dec; 7(2):121-6. PubMed ID: 18035321
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of vascular damage in SSc--implications for vascular treatment strategies.
    Guiducci S; Distler O; Distler JH; Matucci-Cerinic M
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v18-20. PubMed ID: 18784130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
    Distler JH; Distler O
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i48-51. PubMed ID: 19995744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma.
    Ghosh AK; Bhattacharyya S; Lakos G; Chen SJ; Mori Y; Varga J
    Arthritis Rheum; 2004 Apr; 50(4):1305-18. PubMed ID: 15077315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pulmonary arterial hypertension in systemic sclerosis.
    Lambova S; Müller-Ladner U
    Autoimmun Rev; 2010 Sep; 9(11):761-70. PubMed ID: 20601197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis.
    Skhirtladze C; Distler O; Dees C; Akhmetshina A; Busch N; Venalis P; Zwerina J; Spriewald B; Pileckyte M; Schett G; Distler JH
    Arthritis Rheum; 2008 May; 58(5):1475-84. PubMed ID: 18438865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?
    Yamamoto T
    Arch Dermatol Res; 2006 Feb; 297(8):333-44. PubMed ID: 16402183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The immunobiology of systemic sclerosis.
    Gu YS; Kong J; Cheema GS; Keen CL; Wick G; Gershwin ME
    Semin Arthritis Rheum; 2008 Oct; 38(2):132-60. PubMed ID: 18221988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts.
    Akhmetshina A; Dees C; Pileckyte M; Szucs G; Spriewald BM; Zwerina J; Distler O; Schett G; Distler JH
    Arthritis Rheum; 2008 Aug; 58(8):2553-64. PubMed ID: 18668558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc?
    Abraham D
    Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v8-9. PubMed ID: 18784153
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An increased transforming growth factor beta receptor type I:type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma.
    Pannu J; Gore-Hyer E; Yamanaka M; Smith EA; Rubinchik S; Dong JY; Jablonska S; Blaszczyk M; Trojanowska M
    Arthritis Rheum; 2004 May; 50(5):1566-77. PubMed ID: 15146427
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathophysiology of scleroderma: an update.
    Haustein UF; Anderegg U
    J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):1-8. PubMed ID: 9731958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genomic analyses facilitate identification of receptors and signalling pathways for growth differentiation factor 9 and related orphan bone morphogenetic protein/growth differentiation factor ligands.
    Mazerbourg S; Hsueh AJ
    Hum Reprod Update; 2006; 12(4):373-83. PubMed ID: 16603567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis.
    Yoshizaki A; Yanaba K; Yoshizaki A; Iwata Y; Komura K; Ogawa F; Takenaka M; Shimizu K; Asano Y; Hasegawa M; Fujimoto M; Sato S
    Arthritis Rheum; 2010 Aug; 62(8):2476-87. PubMed ID: 20506342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Macro- and microvascular disease in systemic sclerosis.
    Kavian N; Batteux F
    Vascul Pharmacol; 2015 Aug; 71():16-23. PubMed ID: 26044180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytokines as therapeutic targets for the gastrointestinal manifestations of scleroderma.
    Raoul JM; Verma M; Tan E; Peterson TC
    Can J Gastroenterol; 2004 Jan; 18(1):22-4. PubMed ID: 14760427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The pathogenesis of systemic sclerosis.
    Katsumoto TR; Whitfield ML; Connolly MK
    Annu Rev Pathol; 2011; 6():509-37. PubMed ID: 21090968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ubiquitination in Scleroderma Fibrosis and Its Treatment.
    Long Y; Chen W; Du Q; Zuo X; Zhu H
    Front Immunol; 2018; 9():2383. PubMed ID: 30386338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.